Cours de l'action Gilead Sciences, Inc. (GILD)

Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops, and commercializes innovative medicines addressing unmet medical needs in the United States, Europe, and other international markets. The company focuses primarily on life-threatening infectious diseases, with its core portfolio centered on treatments for HIV, hepatitis B, and hepatitis C, including blockbuster drugs like Sovaldi and newer combination regimens that serve as standards of care. Gilead has expanded into oncology through strategic acquisitions, such as Kite Pharma for CAR-T cell therapies Yescarta and Tecartus, and Immunomedics for Trodelvy, targeting breast and bladder cancers. Recent advancements include the FDA approval of Yeztugo (lenacapavir), a twice-yearly HIV prevention drug (PrEP), and positive European Medicines Agency opinions, positioning it to potentially add billions to future sales. With a workforce of approximately 17,600 employees, Gilead Sciences plays a pivotal role in the healthcare sector by advancing therapies in virology and oncology, contributing significantly to global public health efforts against infectious diseases and cancer. Financially robust, it maintains strong revenue streams and a consistent dividend policy, underscoring its stability in the biopharmaceutical industry.